ClinicalTrials.gg

Program

YJ001

A development code. Also written as “YJ001 for Spray Use”, “YJ001 Spray 240 mg/day” and “YJ001 Spray 480 mg/day”.

Its studies are mostly in Neuralgia · Diabetes Mellitus, led by 3 companies.

Furthest: phase 3, since Sep 20, 20264 company-led studies, 2 open or runningNext primary completion: Aug 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zhejiang Hanmai Pharmaceutical Technology22 open or runningphase 3since Sep 20, 2026Mar 19, 2024Aug 30, 2028phase 3 · NCT07859111
Yuejia Pharmaceuticals (USA)10 open or runningphase 1since Jun 28, 2022Jun 28, 2022none ahead
Zhejiang Yuejia Pharmaceuticals10 open or runningphase 2since Sep 20, 2026Sep 20, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 28, 2022First study: phase 1 study in Safety and TolerabilityNew to Yuejia Pharmaceuticals (USA)Yuejia Pharmaceuticals (USA) · NCT05451667 · 32 enrolled · United States
  2. Mar 19, 2024Zhejiang Hanmai Pharmaceutical Technology's first study: phase 1 study in Diabetes MellitusNew to Zhejiang Hanmai Pharmaceutical TechnologyZhejiang Hanmai Pharmaceutical Technology · NCT06361108 · 24 planned · United States
  3. Sep 20, 2026Phase 3 study in Diabetic Peripheral Neuropathic Pain (DPNP)Phase 3 reachedZhejiang Hanmai Pharmaceutical Technology · NCT07859111 · 400 planned · China
  4. Sep 20, 2026Zhejiang Yuejia Pharmaceuticals's first study: phase 2 study in Diabetic Peripheral Neuropathic Pain (DPNP)New to Zhejiang Yuejia PharmaceuticalsZhejiang Yuejia Pharmaceuticals · NCT07858344 · 196 enrolled · China

Ahead

  1. Aug 30, 2028Primary completion: phase 3 study in Diabetic Peripheral Neuropathic Pain (DPNP)Zhejiang Hanmai Pharmaceutical Technology · NCT07859111

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07859111Diabetic Peripheral Neuropathic Pain (DPNP) · China3RecruitingZhejiang Hanmai Pharmaceutical TechnologyAug 30, 2028400
NCT07858344Diabetic Peripheral Neuropathic Pain (DPNP) · China2CompletedZhejiang Yuejia PharmaceuticalsDec 27, 2024196
NCT06361108Diabetes Mellitus · United States1RecruitingZhejiang Hanmai Pharmaceutical TechnologyDec 20, 202524
NCT05451667Safety and Tolerability · United States1CompletedYuejia Pharmaceuticals (USA)Dec 20, 202232

How it is read

Names in the registry

  • “YJ001 for Spray Use”, 2 entries
  • “YJ001 Spray 240 mg/day”, 1 entry
  • “YJ001 Spray 480 mg/day”, 1 entry
  • “YJ001 Spray 960 mg/day”, 1 entry
  • “YJ001 spray”, 1 entry

Codes read as this program: YJ001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
YJ001 (Zhejiang Hanmai Pharmaceutical Technology): development program | ClinicalTrials.gg